145 related articles for article (PubMed ID: 26970563)
1. Identification of potential breast cancer markers in nipple discharge by protein profile analysis using two-dimensional nano-liquid chromatography/nanoelectrospray ionization-mass spectrometry.
Kurono S; Kaneko Y; Matsuura N; Oishi H; Noguchi S; Kim SJ; Tamaki Y; Aikawa T; Kotsuma Y; Inaji H; Matsuura S
Proteomics Clin Appl; 2016 May; 10(5):605-13. PubMed ID: 26970563
[TBL] [Abstract][Full Text] [Related]
2. Identification of microRNAs in Nipple Discharge as Potential Diagnostic Biomarkers for Breast Cancer.
Zhang K; Zhao S; Wang Q; Yang HS; Zhu J; Ma R
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S536-44. PubMed ID: 25976861
[TBL] [Abstract][Full Text] [Related]
3. Detection and identification of potential biomarkers of breast cancer.
Fan Y; Wang J; Yang Y; Liu Q; Fan Y; Yu J; Zheng S; Li M; Wang J
J Cancer Res Clin Oncol; 2010 Aug; 136(8):1243-54. PubMed ID: 20237941
[TBL] [Abstract][Full Text] [Related]
4. Fine Needle Aspiration Combined With Matrix-assisted Laser Desorption Ionization Time-of-Flight/Mass Spectrometry to Characterize Lipid Biomarkers for Diagnosing Accuracy of Breast Cancer.
Cho YT; Su H; Chiang YY; Shiea J; Yuan SF; Hung WC; Yeh YT; Hou MF
Clin Breast Cancer; 2017 Aug; 17(5):373-381.e1. PubMed ID: 28648841
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
6. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS.
Sauter ER; Shan S; Hewett JE; Speckman P; Du Bois GC
Int J Cancer; 2005 May; 114(5):791-6. PubMed ID: 15609313
[TBL] [Abstract][Full Text] [Related]
8. Towards a proteome signature for invasive ductal breast carcinoma derived from label-free nanoscale LC-MS protein expression profiling of tumorous and glandular tissue.
Röwer C; Vissers JP; Koy C; Kipping M; Hecker M; Reimer T; Gerber B; Thiesen HJ; Glocker MO
Anal Bioanal Chem; 2009 Dec; 395(8):2443-56. PubMed ID: 19876624
[TBL] [Abstract][Full Text] [Related]
9. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.
Schaaij-Visser TB; de Wit M; Lam SW; Jiménez CR
Biochim Biophys Acta; 2013 Nov; 1834(11):2242-58. PubMed ID: 23376433
[TBL] [Abstract][Full Text] [Related]
10. Differentiation between genetic mutations of breast cancer by breath volatolomics.
Barash O; Zhang W; Halpern JM; Hua QL; Pan YY; Kayal H; Khoury K; Liu H; Davies MP; Haick H
Oncotarget; 2015 Dec; 6(42):44864-76. PubMed ID: 26540569
[TBL] [Abstract][Full Text] [Related]
11. Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.
Hu X; Zhang Y; Zhang A; Li Y; Zhu Z; Shao Z; Zeng R; Xu LX
OMICS; 2009 Aug; 13(4):291-300. PubMed ID: 19624269
[TBL] [Abstract][Full Text] [Related]
12. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach.
Kadowaki M; Sangai T; Nagashima T; Sakakibara M; Yoshitomi H; Takano S; Sogawa K; Umemura H; Fushimi K; Nakatani Y; Nomura F; Miyazaki M
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1105-15. PubMed ID: 21253761
[TBL] [Abstract][Full Text] [Related]
13. ErbB-2 protein levels in nipple discharge: role in diagnosis of early breast cancer.
Inaji H; Koyama H; Motomura K; Noguchi S; Mori Y; Kimura Y; Sugano K; Ohkura H
Tumour Biol; 1993; 14(5):271-8. PubMed ID: 7901888
[TBL] [Abstract][Full Text] [Related]
14. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid.
Alexander H; Stegner AL; Wagner-Mann C; Du Bois GC; Alexander S; Sauter ER
Clin Cancer Res; 2004 Nov; 10(22):7500-10. PubMed ID: 15569980
[TBL] [Abstract][Full Text] [Related]
15. A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient.
Zhou J; Trock B; Tsangaris TN; Friedman NB; Shapiro D; Brotzman M; Chan-Li Y; Chan DW; Li J
Breast Cancer Res Treat; 2010 Aug; 123(1):73-86. PubMed ID: 19902353
[TBL] [Abstract][Full Text] [Related]
16. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer.
Mbeunkui F; Metge BJ; Shevde LA; Pannell LK
J Proteome Res; 2007 Aug; 6(8):2993-3002. PubMed ID: 17608509
[TBL] [Abstract][Full Text] [Related]
17. Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.
Gromov P; Gromova I; Bunkenborg J; Cabezon T; Moreira JM; Timmermans-Wielenga V; Roepstorff P; Rank F; Celis JE
Mol Oncol; 2010 Feb; 4(1):65-89. PubMed ID: 20005186
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis shows down-regulations of cytoplasmic carbonic anhydrases, CAI and CAII, are early events of colorectal carcinogenesis but are not correlated with lymph node metastasis.
Wang N; Chen Y; Han Y; Zhao Y; Liu Y; Guo K; Jiang Y
Tumori; 2012 Nov; 98(6):783-91. PubMed ID: 23389367
[TBL] [Abstract][Full Text] [Related]
19. Identification of differentially-expressed proteins between early submucosal non-invasive and invasive colorectal cancer using 2D-DIGE and mass spectrometry.
Zhang J; Song MQ; Zhu JS; Zhou Z; Xu ZP; Chen WX; Chen NW
Int J Immunopathol Pharmacol; 2011; 24(4):849-59. PubMed ID: 22230392
[TBL] [Abstract][Full Text] [Related]
20. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
